GlassScriptPhysician profile
Serge Menkin
NPI 1881670784
$3,471.17
in general payments reported to CMS, 2019-2025
32 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $464 · 2021: $593 · 2022: $461 · 2023: $341 · 2024: $380 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $952.40 | 2019-2024 | Xtampza |
| Horizon Therapeutics Plc | $479.14 | 2019-2022 | |
| Boston Scientific Corporation | $233.36 | 2020-2025 | General - Pain Management |
| Nuvasive, INC. | $194.50 | 2019-2020 | |
| Nalu Medical, INC. | $152.56 | 2021-2023 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $139.66 | 2024 | Mild Device Kit |
| Daiichi Sankyo INC. | $121.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $114.55 | 2021 | |
| Spr Therapeutics, INC | $112.92 | 2024 | Sprint Pns System |
| Medtronic, INC. | $110.03 | 2025 | Inceptiv |
| Scilex Pharmaceuticals INC. | $97.07 | 2019-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.81 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $68.44 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $67.07 | 2022-2023 | Quviviq |
| Pfizer INC. | $64.54 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $64.05 | 2021-2023 | Gralise |
| Indivior INC. | $62.03 | 2019-2021 | |
| Foundation Fusion Solutions, LLC | $52.83 | 2023-2024 | |
| Sentynl Therapeutics, INC. | $49.15 | 2019 | |
| Depuy Synthes Sales INC. | $37.79 | 2022 | |
| Medline Industries LP | $33.24 | 2025 | |
| Virtus Pharmaceuticals LLC | $23.77 | 2021 | |
| Abbott Laboratories | $18.45 | 2024 | Eterna |
| Zimmer Biomet Holdings, INC. | $17.54 | 2022 | |
| Kaleo, INC. | $17.22 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.39 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.35 | 2023 | Exparel, Zilretta, Iovera |
| Shionogi INC | $15.13 | 2019 | |
| Spinefrontier, INC. | $13.22 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $12.95 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.98 | 2022 | |
| Bioventus LLC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Menkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.